A decade of immune-checkpoint inhibitors in cancer therapy

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723

Cancer immunotherapy: moving beyond current vaccines

Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472

Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma

Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., Cowey, C. L., Dalle, S., Schenker, M., Chiarion-Sileni, V., Marquez-Rodas, I., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709030 · Cited by 2,246

Adjuvant pembrolizumab versus placebo in resected stage III melanoma

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,100

Anti-PD-1: When to Stop Treatment

Jansen, Y. J. L., van der Veldt, A. A. M., Awada, G., & Neyns, B. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01264-6 · Cited by 19

Cancer-Associated Fibroblasts and Squamous Epithelial Cells Constitute a Unique Microenvironment in a Mouse Model of Inflammation-Induced Colon Cancer

Vega, P. N., Nilsson, A., Kumar, M. P., Niitsu, H., Simmons, A. J., Ro, J., Wang, J., Chen, Z., Joughin, B. A., Li, W., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.878920 · Cited by 19

Discovery of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one and 3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one derivatives as novel ENPP1 inhibitors

Jung, J. E., Jang, Y., Jeong, H. J., Kim, S. J., Park, K. C., Oh, D. H., Yu, A.-R., Park, C. S., & Han, S. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128947 · Cited by 19

Immunization of Mice with Gold Nanoparticles Conjugated to Thermostable Cancer Antigens Prevents the Development of Xenografted Tumors

Dykman, L. A., Staroverov, S. A., Kozlov, S., Fomin, A. S., Chumakov, D. S., Габалов, К. П., Kozlov, Y. S., Soldatov, D., & Khlebtsov, N. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214313 · Cited by 18

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy

Mortensen, R. E. J., Holmström, M. O., Lisle, T. L., Hasselby, J. P., Willemoe, G. L., Met, Ö., Svane, I. M., Johansen, J. S., Nielsen, D. L., Chen, I. M., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006432 · Cited by 19

Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential

Jou, E. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00146 · Cited by 19

Antibiotic Exposure Concurrently with Anti-PD1 Blockade Therapy Reduces Overall Survival in Patients with Child–Pugh Class A Advanced Hepatocellular Carcinoma

Alshammari, K. M., Alotaibi, F., Alsugheir, F., Aldawoud, M., Alolayan, A. A. M., Algarni, M., Sabatin, F., Mohammad, M. F., Alosaimi, A., Sanai, F. M., et al. (2023) · Cancers · doi:10.3390/cancers16010133 · Cited by 19

Establishing mouse and human oral esophageal organoids to investigate the tumor immune response

Jiang, Y., Zhao, H., Kong, S., Zhou, D., Dong, J., Cheng, Y., Zhang, S., Wang, F., Kalra, A., Yang, N., et al. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050319 · Cited by 19

Glioblastoma and Immune Checkpoint Inhibitors: A Glance at Available Treatment Options and Future Directions

Rodriguez, S. M. B., Tătăranu, L. G., Kamel, A., Turliuc, Ș., Rizea, R. E., & Dricu, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910765 · Cited by 20

Dying to survive: harnessing inflammatory cell death for better immunotherapy

Cheng, L., Wang, Y., & Zhang, Y. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.01.012 · Cited by 19

Engineered elastin-like polypeptide-based hydrogel delivering chemotherapeutics and PD-L1 antibodies for potentiated cancer immunotherapy

Chen, J., Cui, M., He, L., Mu, Y., Hu, N., & Guan, X. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb01974h · Cited by 18

An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma

Pham, J. P., Staeger, R., Joshua, A. M., Liu, J., da Silva, I. P., Dummer, R., & Goldinger, S. M. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115121 · Cited by 18

Leptomeningeal Disease: Current Approaches and Future Directions

Sener, U. T., Wilcox, J. A., & Boire, A. A. (2025) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-025-01412-y · Cited by 18

Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with Elisa

Millet, A., Khoudour, N., Guitton, J., Lebert, D., Goldwasser, F., Blanchet, B., & Machon, C. (2021) · Biomedicines · doi:10.3390/biomedicines9060621 · Cited by 18

m6A Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Pancreatic Cancer

Sun, M., Xie, M., Zhang, T., Wang, Y., Huang, W., & Xia, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.739768 · Cited by 18

Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer

Mulvey, A., Muggeo-Bertin, E., Berthold, D., & Herrera, F. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859785 · Cited by 18

Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients: Analyses of Tumour Cell Determinants Correlating With Efficacy In Vitro and In Vivo

Lanuza, P. M., Alonso, M. H., Hidalgo, S., Uranga-Murillo, I., García‐Mulero, S., Arnau, R., Santos, C., Sanjuán, X., Santiago, L., Comas, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.890836 · Cited by 18

T2 and T2⁎ mapping and weighted imaging in cardiac MRI

Topriceanu, C., Pierce, I., Moon, J., & Captur, G. (2022) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2022.07.012 · Cited by 19

A Shear-Thinning Biomaterial-Mediated Immune Checkpoint Blockade

Wu, Q., Qu, M., Kim, H., Zhou, X., Jiang, X., Chen, Y., Zhu, J., Ren, L. M., Wolter, T., Kang, H., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c06137 · Cited by 18

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma

Chen, Y., Tucker, M. D., Brown, L. C., Yasin, H., Ancell, K. K., Armstrong, A. J., Beckermann, K. E., Davis, N. B., Harrison, M. R., Kaiser, E., et al. (2022) · Cancers · doi:10.3390/cancers14153830 · Cited by 19

Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors

Makrakis, D., Rounis, K., Tsigkas, A.-P., Georgiou, A., Galanakis, N., Tsakonas, G., Ekman, S., Papadaki, C., Monastirioti, A. A., Kontogianni, M. D., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0277708 · Cited by 18

Unveiling the epigenomic mechanisms of acquired platinum‐resistance in high‐grade serous ovarian cancer

Silva, R., Glennon, K., Metoudi, M., Moran, B., Salta, S., Slattery, K., Treacy, A. D., Martin, T., Shaw, J., Doran, P., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34496 · Cited by 18

Immune microenvironment remodeling after radiation of a progressing brain metastasis

Hudson, W. H., Olson, J. J., & Sudmeier, L. J. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101054 · Cited by 18

Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors

Silverstein, J. F., Wright, F., Wang, M., Young, A., Kim, D., de Dios, K., Brondfield, S., & Quandt, Z. (2023) · The Oncologist · doi:10.1093/oncolo/oyad135 · Cited by 18

Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review

Profili, N. I., Castelli, R., Gidaro, A., Merella, A., Manetti, R., Palmieri, G., Maioli, M., & Delitala, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12155161 · Cited by 18

Construction of Immune Infiltration-Related LncRNA Signatures Based on Machine Learning for the Prognosis in Colon Cancer

Liu, Z., Petinrin, O. O., Toseef, M., Chen, N., & Wong, K. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10516-4 · Cited by 19

The use of histotripsy as intratumoral immunotherapy beyond tissue ablation—the rationale for exploring the immune effects of histotripsy

Osada, T., Jiang, X., Zhao, Y., Chen, M., Kreager, B. C., Wu, H., Kim, H., Ren, J., Snyder, J. C., Zhong, P., et al. (2023) · International Journal of Hyperthermia · doi:10.1080/02656736.2023.2263672 · Cited by 18

The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects

Ertl, C., Ruf, T., Mentzer, D., Kong, M., Kramer, R., von Bergwelt‐Baildon, M., Subklewe, M., Tomsitz, D., Ascierto, P. A., Dummer, R., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113505 · Cited by 18

Engineered polymer nanoparticles as artificial chaperones facilitating the selective refolding of denatured enzymes

Li, Y., Yin, D., Lee, S. Y., & Lv, Y. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2403049121 · Cited by 18

Obesity, dysbiosis and inflammation: interactions that modulate the efficacy of immunotherapy

Yende, A. S., & Sharma, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1444589 · Cited by 19

New avenues for cancer immunotherapy: Cell-mediated drug delivery systems

Zhang, H., Grippin, A., Sun, M., Ma, Y., Kim, B. Y. S., Teng, L., Jiang, W., & Yang, Z. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.037 · Cited by 19

The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges

Bouferraa, Y., Chedid, A., Amhaz, G., Lakkiss, A. E., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158036 · Cited by 18

The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials

Dubois, M., Liscia, N., Brunetti, O., Ziranu, P., Lai, E., Argentiero, A., Mazza, E. A., Cascinu, S., Silvestris, N., Gardini, A. C., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103674 · Cited by 18

First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer

Sullivan, R. J., Yeku, O., Teoh, D. K., Gupta, S., Matei, D. E., Laino, A. S., Sun, J., Zhu, L., Van, L. M., Pascarella, S., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf115 · Cited by 17

Silver Nanoparticles as Anticancer Agents: Mechanisms Insight, Current Studies, and Limitations

Okur, E. E., Akdaşçi, E., Eker, F., Bechelany, M., & Karav, S. (2026) · Pharmaceuticals · doi:10.3390/ph19020241 · Cited by 17

ERAP2 Inhibition Induces Cell-Surface Presentation by MOLT-4 Leukemia Cancer Cells of Many Novel and Potentially Antigenic Peptides

Temponeras, I., Stamatakis, G. M., Samiotaki, M. K., Georgiadis, D., Pratsinis, H., Panayotou, G., & Stratikos, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031913 · Cited by 17

Circadian and Immunity Cycle Talk in Cancer Destination: From Biological Aspects to In Silico Analysis

Mirian, M., Hariri, A., Yadollahi, M., & Kohandel, M. (2022) · Cancers · doi:10.3390/cancers14061578 · Cited by 17

Adverse Events Associated with Immune Checkpoint Inhibitors: Overview of Systematic Reviews

Kanji, S., Morin, S., Agtarap, K., Purkayastha, D., Thabet, P., Bossé, D., Wang, X., Lunny, C., & Hutton, B. (2022) · Drugs · doi:10.1007/s40265-022-01707-1 · Cited by 18

Immunosuppressive Extracellular Vesicles as a Linking Factor in the Development of Tumor and Endometriotic Lesions in the Gynecologic Tract

Soroczyńska, K., Zaręba, Ł., Długołęcka, M., & Czystowska, M. (2022) · Cells · doi:10.3390/cells11091483 · Cited by 17

Targeted Molecular Construct for Bioorthogonal Theranostics of PD-L1-Expressing Cancer Cells

Chow, S. Y., & Unciti‐Broceta, A. (2022) · JACS Au · doi:10.1021/jacsau.2c00328 · Cited by 17

Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells

Martins, C. P., Silva, M. C., Rasbach, E., Singh, P. K., Itoh, Y., Williams, J. B., Statham, E., Meurer, A., Martinez, D. V., Brandenburg, A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16776-1 · Cited by 17

Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice

Chen, J.-S., Hsieh, Y.-C., Chou, C.-H., Wu, Y., Yang, M.-H., Chu, S.-H., Chao, Y.-S., & Chen, C.-N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810677 · Cited by 18

Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy

Louie, B. H., Kato, S., Kim, K. H., Lim, H. J., Okamura, R., Eskander, R. N., Botta, G. P., Patel, H., Lee, S., Lippman, S. M., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00309-0 · Cited by 17

Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis

Noori, M., Mahjoubfar, A., Azizi, S., Fayyaz, F., & Rezaei, N. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109317 · Cited by 19

Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study

Zhu, J., Wu, J., Chen, P., You, K., Su, J., Gao, Z., Bi, Z., & Feng, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109350 · Cited by 18

Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

Corbacho, J. G., Indacochea, A., González‐Navarro, E. A., Ruiz, I. V., Moreno, D., Pesántez, D., Angelats, L., Modrego-Sánchez, A., Sanfeliu, E., Castillo, O., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03360-9 · Cited by 18

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1

Mukherjee, D., Romano, E., Walshaw, R. C., Zeef, L. A. H., Banyard, A., Kitcatt, S. J., Cheadle, E. J., Tuomela, K., Pendharkar, S., Al-Deka, A., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2223094 · Cited by 17

Thymus-derived hormonal and cellular control of cancer

Savino, W., & Lepletier, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1168186 · Cited by 17

Noncoding RNAs as an emerging resistance mechanism to immunotherapies in cancer: basic evidence and therapeutic implications

Wang, M., Yu, F., & Li, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1268745 · Cited by 17

d-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunity

Dong, W., Lin, M., Zhang, R., Sun, X., Li, H., Liu, T., Xu, Y., & Lv, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216883 · Cited by 18

Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis

Iyer, K. A., Ivanov, J. M., Tenchov, R., Ralhan, K., Rodríguez, Y., Sasso, J. M., Scott, S. A., & Zhou, Q. A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00568 · Cited by 20

Machine Learning–Directed Conversion of Glioblastoma Cells to Dendritic Cell–Like Antigen-Presenting Cells as Cancer Immunotherapy

Liu, T., Jin, D., Le, S. B., Chen, D., Sebastian, M., Riva, A., Liu, R., & Tran, D. D. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0721 · Cited by 18

Multifunctional single-component photosensitizers as metal-free ferroptosis inducers for enhanced photodynamic immunotherapy

Fang, L., Meng, Q., Wang, J., Tu, Y., Hong, Q., Diao, Y., Li, W., Wen, H., Jin, F., Hang, L., et al. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.07.034 · Cited by 17

Exploring the Immunoresponse in Bladder Cancer Immunotherapy

Ruiz-Lorente, I., Gimeno, L., López-Abad, A., Cubillana, P. L., Aparicio, T. F., Egea, L. J. A., Avilés, J. M., Iñiguez, G. D., Martínez-Valls, P. L. G., Server, G., et al. (2024) · Cells · doi:10.3390/cells13231937 · Cited by 18

Harnessing EV communication to restore antitumor immunity

Massaro, C., Min, W., Pegtel, D. M., & Baglio, S. R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113838 · Cited by 17

Prognostic Value of PD-L1, PD-1 and CD8A in Canine Diffuse Large B-Cell Lymphoma Detected by RNAscope

Aresu, L., Marconato, L., Martini, V., Fanelli, A., Licenziato, L., Foiani, G., Melchiotti, E., Nicoletti, A., & Vascellari, M. (2021) · Veterinary Sciences · doi:10.3390/vetsci8070120 · Cited by 17

Emerging Role of Epigenetic Alterations as Biomarkers and Novel Targets for Treatments in Pancreatic Ductal Adenocarcinoma

Roalsø, M. T. T., Hald, Ø. H., Alexeeva, M., & Søreide, K. (2022) · Cancers · doi:10.3390/cancers14030546 · Cited by 18

The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma

Neth, B. J., Webb, M., Parney, I. F., & Sener, U. T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041134 · Cited by 17

Cardiovascular adverse effects of immunotherapy in cancer: insights and implications

Du, H., Wang, J., & Wang, Z. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1601808 · Cited by 19

Cell Therapies in Bladder Cancer Management

Morales, L., & Paramio, J. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062818 · Cited by 16

Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid—A Retrospective, Monocentric Study

Schauer, F., Rafei-Shamsabadi, D. A., Mai, S., Mai, Y., Izumi, K., Meiß, F., & Kiritsi, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953546 · Cited by 16

Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy

Pradeep, J., Win, T. T., Aye, S. N., & Sreeramareddy, C. T. (2022) · Journal of Cancer · doi:10.7150/jca.72210 · Cited by 17

Anti–PD-L1 Antibody and/or 17β-Estradiol Treatment Induces Changes in the Gut Microbiome in MC38 Colon Tumor Model

Song, C., Kim, N., Nam, R. H., Choi, S. I., Jang, J. Y., Choi, J., & Lee, H. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2022.1427 · Cited by 16

TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments

Liao, P., Jiang, M., Islam, M. S., Wang, Y., & Chen, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1097090 · Cited by 16

Creating an Innovative Artificial Intelligence–Based Technology (TCRact) for Designing and Optimizing T Cell Receptors for Use in Cancer Immunotherapies: Protocol for an Observational Trial

Bujak, J. K., Kłęk, S., Balawejder, M., Kociniak, A., Wilkus, K., Szatanek, R., Orzeszko, Z., Welanyk, J., Torbicz, G., Jęckowski, M., et al. (2023) · JMIR Research Protocols · doi:10.2196/45872 · Cited by 16

Structure–Activity Relationship of Truncated 2,8-Disubstituted-Adenosine Derivatives as Dual A2A/A3 Adenosine Receptor Antagonists and Their Cancer Immunotherapeutic Activity

Kim, G., Hou, X., Byun, W. S., Kim, G., Jarhad, D. B., Lee, G., Hyun, Y. E., Yu, J., Lee, C., Qu, S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00806 · Cited by 16

Genetically engineered eukaryocyte-bacteria hybrid membrane-camouflaged nanoemulsion for three-pronged synergistic cancer therapy

Zhang, Y., Liao, Y., Bai, F., Xing, S., Wang, M., Dang, Z., Lin, J., & Huang, P. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102076 · Cited by 16

HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice

Long, J., Chen, X., He, M., Ou, S., Zhao, Y., Yan, Q., Ma, M., Chen, J., Qin, X., Zhou, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46558-4 · Cited by 18

Novel Clinical Trials and Approaches in the Management of Glioblastoma

Valerius, A. R., Webb, L. M., & Sener, U. T. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01519-4 · Cited by 17

Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer

Wescott, E. C., Sun, X., Ericsson, P. I. G., Hanna, A., Taylor, B. C., Sanchez, V. M., Bronzini, J., Opalenik, S. R., Sanders, M. E., Wulfkuhle, J. D., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0468 · Cited by 18

Synergistic Combination of Oral Transcytotic Nanomedicine and Histone Demethylase Inhibitor for Enhanced Cancer Chemoimmunotherapy

Zhang, J., Wei, Q., Piao, Y., Shao, S., Zhou, Z., Tang, J., Xiang, J., & Shen, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c14816 · Cited by 16

Pre-treatment neutrophil-lymphocyte and platelet-lymphocyte ratios as additional markers for breast cancer progression: A retrospective cohort study

Anwar, S. L., Cahyono, R., Avanti, W. S., Budiman, H. Y., Harahap, W. A., & Aryandono, T. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.01.092 · Cited by 16

Therapeutic Ultrasound-Enhanced Immune Checkpoint Inhibitor Therapy

Yuan, J., Ye, D., Chen, S., & Chen, H. (2021) · Frontiers in Physics · doi:10.3389/fphy.2021.636985 · Cited by 18

The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity

Edwards, C., Sette, A., Cox, C. T., Fiore, B. D., Wyre, C., Sydoruk, D., Yadin, D., Hayes, P., Stelter, S., Bartlett, P. D., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01684-4 · Cited by 16

Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations

Principe, D. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-15714-5 · Cited by 17

Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors

Ji, X., Jiang, W., Wang, J., Zhou, B., Ding, W., Liu, S., Huang, H., Chen, G., & Sun, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1106644 · Cited by 18

Protocol for Efficient Generation of Chimeric Antigen Receptor T Cells with Multiplexed Gene Silencing by Epigenome Editing

Azcona, M. S. R., & Mussolino, C. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-4051-7_11 · Cited by 3

LAG Time in the Era of Immunotherapy—New Molecular Insights Into the Immunosuppression Mechanism of Lymphocyte Activation Gene‐3

Luca, V. C. (2025) · Immunological Reviews · doi:10.1111/imr.70002 · Cited by 15

Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy

Zhang, S., Yan, C., Millar, D. G., Yang, Q., Heather, J., Langenbucher, A., Morton, L. T., Sepulveda, S., Alpert, E. J., Whelton, L. R., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2200 · Cited by 15

Barring the gates to the battleground: DDR1 promotes immune exclusion in solid tumors

Wagner, D. L., & Klotzsch, E. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00877-4 · Cited by 15

From Tumor Cells to Endothelium and Gut Microbiome: A Complex Interaction Favoring the Metastasis Cascade

Sater, A. H. A., Bouferraa, Y., Amhaz, G., Haibe, Y., Lakkiss, A. E., & Shamseddine, A. I. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.804983 · Cited by 16

Low Level FLT3LG is a Novel Poor Prognostic Biomarker for Cervical Cancer with Immune Infiltration

Chen, L., Huang, Y., Dong, B., Gu, Y. L., Li, Y., Cang, W., Sun, P., & Xiang, Y. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s384908 · Cited by 14

Mesenchymal-endothelial nexus in breast cancer spheroids induces vasculogenesis and local invasion in a CAM model

Li, A., Muenst, S. E., Hoffman, J., Starck, L., Sarem, M., Fischer, A., Hütter, G., & Shastri, V. P. (2022) · Communications Biology · doi:10.1038/s42003-022-04236-5 · Cited by 19

Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes

Akhuba, L. G., Tigai, Z. G., & Shek, D. (2022) · Biomedicines · doi:10.3390/biomedicines10123196 · Cited by 15

Agonistic and antagonistic targeting of immune checkpoint molecules differentially regulate osteoclastogenesis

Brom, V. C., Strauss, A. C., Sieberath, A., Salber, J., Burger, C., Wirtz, D. C., & Schildberg, F. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.988365 · Cited by 15

The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes

Kuszczak, B., Wróbel, T., Wicherska‐Pawłowska, K., & Rybka, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054708 · Cited by 15

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma

Frías, A., Leo, L. D., Antoranz, A., Nazerai, L., Carretta, M., Bodemeyer, V., Pagliuca, C., Dahl, C., Claps, G., Mandelli, G. E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006389 · Cited by 15

Anthelmintic Drugs as Emerging Immune Modulators in Cancer

Stolfi, C., Pacifico, T., Luiz-Ferreira, Â., Monteleone, G., & Laudisi, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076446 · Cited by 19

VISTA Ligation Reduces Antitumor T-Cell Activity in Pancreatic Cancer

Digomann, D., Strack, J., Heiduk, M., Plesca, I., Rupp, L., Reiche, C., Nicolaus, S., Beer, C., Sommer, U. J., Schmitz, M., et al. (2023) · Cancers · doi:10.3390/cancers15082326 · Cited by 17

Liquid-liquid phase separation throws novel insights into treatment strategies for skin cutaneous melanoma

Liu, J.-L., Pei, S., Zhang, P., Jiang, K., Luo, B., Hou, Z., Yao, G., & Tang, J. (2023) · BMC Cancer · doi:10.1186/s12885-023-10847-w · Cited by 15

T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy

Stephen, B., Hajjar, J., Sarda, S., Duose, D. Y., Conroy, J. M., Morrison, C., Alshawa, A., Xu, M., Zarifa, A., Patel, S. P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007236 · Cited by 17

Ultrasensitive interferon-gamma sensor with a bifunctionalized conducting polymer nanobioconjugate for therapy-progress monitoring of cancer patients

Saputra, H. A., Chung, J. H., Kwon, R. J., Jannath, K. A., Park, D., & Shim, Y. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.134739 · Cited by 15

Immune checkpoint inhibition (ICI) in current systemic therapies for hepatocellular carcinoma (HCC)

van Bömmel, F., Berg, T., & Lordick, F. (2023) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2023.08.004 · Cited by 15

Cannabinoids and the endocannabinoid system in immunotherapy: helpful or harmful?

Sarsembayeva, A., & Schicho, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1296906 · Cited by 15

Mechanism-guided fine-tuned microbiome potentiates anti-tumor immunity in HCC

Liu, T., Guo, Y., Liao, Y., & Liu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1333864 · Cited by 16

Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade

Lee, E., Kim, Y. S., Kim, J. H., Woo, K. W., Park, Y.-H., Ha, J.-H., Li, W., Kim, T. I., An, B. K., Cho, H. W., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155370 · Cited by 15

Tumor-targeting bacteria as immune stimulants – the future of cancer immunotherapy?

Mowday, A. M., van de Laak, J., Fu, Z., Henare, K. L., Dubois, L. J., Lambin, P., Theys, J., & Patterson, A. V. (2024) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2024.2311653 · Cited by 16

A Wireless, Multicolor Fluorescence Image Sensor Implant for Real-Time Monitoring in Cancer Therapy

Roschelle, M., Rabbani, R., Gweon, S., Kumar, R., Vercruysse, A., Cho, N. W., Spitzer, M. H., Niknejad, A. M., Stojanovic, V. M., & Anwar, M. (2024) · IEEE Journal of Solid-State Circuits · doi:10.1109/jssc.2024.3435736 · Cited by 15

STING‐Activating Small Molecular Therapeutics for Cancer Immunotherapy

Huang, C., Tong, T., Ren, L., & Wang, H. (2024) · ChemBioChem · doi:10.1002/cbic.202400255 · Cited by 15

Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response

Wofford, W. O., Kim, J., Kim, D., Janneh, A. H., Lee, H. G., Atilgan, F. C., Oleinik, N. V., Kassir, M. F., Saatci, Ö., Chakraborty, P., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114532 · Cited by 15

["Immune checkpoint inhibitors in oncology"].

Daëron, M., & Vivier, É. (2021) · PubMed

Meditating on Cancer Management at the Time of Immunotherapy

Lopci, E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113025

Redefining success: predicting checkpoint inhibitor toxicity to improve patient outcomes

Weidhaas, J. B. (2022) · Immuno Oncology Insights · doi:10.18609/ioi.2022.030

Immunotherapy for cancer

Lee, A. J. X. (2022) · Medicine · doi:10.1016/j.mpmed.2022.10.007 · Cited by 3

Immuno-oncology: A changing paradigm in cancer therapy

Abdel-Rahman, O. M. (2016) · Advances in Modern Oncology Research · doi:10.18282/amor.v2.i6.187 · Cited by 1